tiprankstipranks
MorphoSys AG Joins Forces with Novartis
Company Announcements

MorphoSys AG Joins Forces with Novartis

Morphosys (DE:MOR) has released an update.

Don't Miss Our Christmas Offers:

MorphoSys AG has become a majority-owned subsidiary of Novartis following a successful voluntary public takeover offer at €68.00 per share, with Novartis BidCo AG acquiring a stake of approximately 91.04%. The company also sold the rights to tafasitamab to Incyte for $25 million and announced significant changes to its management board and financial guidance post-takeover, including the expectation of no product sales revenues for 2024. Furthermore, MorphoSys’s development pipeline includes partnerships with Novartis and Anthos Therapeutics on multiple clinical programs in various disease areas.

For further insights into DE:MOR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMorphoSys Shareholders Approve Novartis Merger
Brian Anderson0NDV Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App